Denali Therapeutics Inc (DNLI) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $21.42
• Market Cap: $3.48B
• EPS: $-2.92
• 52-Week High: $23.77
• 52-Week Low: $10.57

Market Sentiment

Denali Therapeutics Inc currently has a Bullish sentiment score of 0.30.

About Denali Therapeutics Inc

Denali Therapeutics Inc. is a prominent biopharmaceutical firm dedicated to developing innovative treatments for neurodegenerative diseases, targeting significant unmet medical needs within this critical healthcare sector. Based in South San Francisco, California, the company employs its proprietary technology platforms to craft disease-modifying therapies that address the underlying biological mechanisms of various neurological disorders. Denali’s robust pipeline includes a range of promisin...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Denali Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does DNLI pay dividends?

Denali Therapeutics Inc (DNLI) does not currently pay a regular dividend.

What is DNLI's market cap?

Denali Therapeutics Inc (DNLI) has a market capitalization of $3.48B with a current stock price of $21.42.